Moving Away from One-Size-Fits-All: Assessing the Use of Pharmacogenetic-Guided Medication Therapy in Pediatric Patients with Chronic Pain

<b>Background/Objectives:</b> Pharmacogenetic (PGx) testing can predict drug efficacy, toxicity, and risk of adverse drug reactions (ADRs). However, PGx-guided prescribing for pediatric chronic pain is underutilized. <b>Methods</b>: We evaluated the rate of deviance from standard drug dosing regimens in children and adolescents with chronic pain based on PGx testing of drug-metabolizing genes. We also assessed the acceptability and feasibility of PGx testing and implementation of PGx-guided recommendations from patient, caregiver, and prescriber perspectives. Finally, we explored whether PGx results could predict self-reported therapeutic responses and/or ADRs to medications. <b>Results</b>: Forty-eight participants aged 8-17 years with chronic pain provided DNA via buccal swab. Genetic variant data for <i>CYP2D6</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> metabolism genes and associated metabolizer status were analyzed with respect to clinical PGx guidelines for dosing recommendations of analgesics and psychotropic medications. Participants, their caregivers, and their prescribers also completed quantitative questionnaires evaluating their experience with PGx testing. Twenty-three (50%) participants were predicted to benefit from non-standard dosing for medications with clinical PGx guidelines. Participants expressed satisfaction with the PGx testing process and felt it was safe and worthwhile. Prescribers also reported that PGx results were relevant for medication choices in 42 (91%) participants. Seven (15%) participants had genotyping results which may have predicted their self-reported therapeutic responses and/or ADRs to specific medications. <b>Conclusions</b>: Though further research on pharmacodynamic associations is required to sufficiently address the complexity of interpatient responses to medications for the treatment of pediatric pain and mental health conditions, PGx testing may be used to inform individualized medication choices based on genetic make-up.

Authors

Institutions

Publication Details

Journal
Children
Published
2025-05-31
DOI
https://doi.org/10.3390/children12060721
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Moving Away from One-Size-Fits-All: Assessing the Use of Pharmacogenetic-Guided Medication Therapy in Pediatric Patients with Chronic Pain

Klaudia Szczech, Naiyi Sun, Danielle Ruskin, Iris Cohn et al.
Children
Pharmaceutical studies and practices
article

Moving Away from One-Size-Fits-All: Assessing the Use of Pharmacogenetic-Guided Medication Therapy in Pediatric Patients with Chronic Pain

Klaudia Szczech, Naiyi Sun, Danielle Ruskin, Iris Cohn, Sierra Scodellaro
article en

Abstract

<b>Background/Objectives:</b> Pharmacogenetic (PGx) testing can predict drug efficacy, toxicity, and risk of adverse drug reactions (ADRs). However, PGx-guided prescribing for pediatric chronic pain is underutilized. <b>Methods</b>: We evaluated the rate of deviance from standard drug dosing regimens in children and adolescents with chronic pain based on PGx testing of drug-metabolizing genes. We also assessed the acceptability and feasibility of PGx testing and implementation of PGx-guided recommendations from patient, caregiver, and prescriber perspectives. Finally, we explored whether PGx results could predict self-reported therapeutic responses and/or ADRs to medications. <b>Results</b>: Forty-eight participants aged 8-17 years with chronic pain provided DNA via buccal swab. Genetic variant data for <i>CYP2D6</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> metabolism genes and associated metabolizer status were analyzed with respect to clinical PGx guidelines for dosing recommendations of analgesics and psychotropic medications. Participants, their caregivers, and their prescribers also completed quantitative questionnaires evaluating their experience with PGx testing. Twenty-three (50%) participants were predicted to benefit from non-standard dosing for medications with clinical PGx guidelines. Participants expressed satisfaction with the PGx testing process and felt it was safe and worthwhile. Prescribers also reported that PGx results were relevant for medication choices in 42 (91%) participants. Seven (15%) participants had genotyping results which may have predicted their self-reported therapeutic responses and/or ADRs to specific medications. <b>Conclusions</b>: Though further research on pharmacodynamic associations is required to sufficiently address the complexity of interpatient responses to medications for the treatment of pediatric pain and mental health conditions, PGx testing may be used to inform individualized medication choices based on genetic make-up.

ChildrenVol. 12(6)
St. Michael's Hospital (CA), University of Toronto (CA), York University (CA), Hospital for Sick Children (CA), Women's College Hospital (CA), St Michael’s Hospital (IE), Unity Health Toronto
Hospital for Sick Children
Good health and well-being
Openalex Percentile: Top 83%
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.